Last reviewed · How we verify
Consolidative immunotherapy
Consolidative immunotherapy enhances anti-tumor immune responses by combining checkpoint inhibition with additional immune-activating strategies to prevent cancer recurrence.
Consolidative immunotherapy enhances anti-tumor immune responses by combining checkpoint inhibition with additional immune-activating strategies to prevent cancer recurrence. Used for Cancer consolidation therapy (specific indication under investigation in phase 3).
At a glance
| Generic name | Consolidative immunotherapy |
|---|---|
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This approach typically involves using immunotherapy agents (such as PD-1/PD-L1 inhibitors) in a consolidation setting after initial treatment to maintain or amplify anti-tumor immunity. The strategy aims to prevent relapse by sustaining T-cell activation and tumor surveillance in patients who have achieved remission or partial response.
Approved indications
- Cancer consolidation therapy (specific indication under investigation in phase 3)
Common side effects
- Immune-related adverse events (irAEs)
- Fatigue
- Pneumonitis
Key clinical trials
- Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer (PHASE3)
- Donor-Derived EBV-Specific T Cells for Life Threatening EBV-lymphoma (OLIP-EBV-TCL-01-HMR01) (NA)
- Evaluation of Impedance Cardiography for Assessing Hemodynamic Shifts in Patients With LA-NSCLC During Treatment.
- Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck (PHASE3)
- Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy (EARLY_PHASE1)
- Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL (PHASE2)
- Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial (PHASE1, PHASE2)
- Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Consolidative immunotherapy CI brief — competitive landscape report
- Consolidative immunotherapy updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI